Age-related differences in disease characteristics and clinical outcomes in polycythemia vera

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 1989-1995

  Stein, Brady L ^a   Saraf, Santosh ^b   Sobol, Urszula ^c   Halpern, Anna ^d   Shammo, Jamile ^e   Rondelli, Damiano ^b   Michaelis, Laura ^c   Odenike, Olatoyosi ^f   Rademaker, Alfred ^a   Zakarija, Anaadriana ^a   McMahon, Brandon ^a   Spivak, Jerry L ^g   Moliterno, Alison R ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

JAK2 V617F; Myeloproliferative neoplasm; Polycythemia; Splanchnic vein thrombosis; Vera; Young

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA; INTERFERON; PEGINTERFERON;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SPLANCHNIC BLOOD FLOW; VEIN THROMBOSIS;

ADULT; AGE FACTORS; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA; MALE; PATIENT OUTCOME ASSESSMENT; POLYCYTHEMIA VERA; PREVALENCE; PRIMARY MYELOFIBROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; VASCULAR DISEASES;

EID: 84879104781     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.759656     Document Type: Article

References (48)

1. LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
2. James C, Ugo V, Le Couedic J P, et al. Aunique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.
3. Kralovics R, Passamonti F, Buser AS, et al. Again-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 200528;352:1779-1790.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
5. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
6. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
7. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
8. Marchioli R, Finazzi G, LandolfiR, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-2232.
9. LandolfiR, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
10. Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, et al. Postpolycythaemic myelofibrosis: Frequency and risk factors for this complication in 116 patients. Br J Haematol 2009;146:504-509.
11. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera:An analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670.
12. Osgood EE. Polycythemia vera:Age relationships and survival. Blood 1965;26:243-256.
13. Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007;25:1048-1053.
14. Teofili L, Foa R, Giona F, et al. Childhood polycythemia vera and essential thrombocythemia: Does their pathogenesis overlap with that of adult patients? Haematologica 2008;93:169-172.
15. Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol 2009;88:713-719.
16. Frezzato M, Ruggeri M, Castaman G, et al. Polycythemia vera and essential thrombocythemia in young patients. Haematologica 1993;78:11-17.
17. Najean Y, Mugnier P, Dresch C, et al. Polycythaemia vera in young people:An analysis of 58 cases diagnosed before 40 years. Br J Haematol 1987;67:285-291.
18. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients :A study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003;88:13-18.
19. Perea G, Remacha A, Besses C, et al. Is polycythemia vera a serious disease in young adults? Haematologica 2001;86:543-544.
20. Ruggeri M, Finotto S, Fortuna S, et al. Treatment outcome in a cohort of young patients with polycythemia vera. Intern Emerg Med 2010;5:411-413.
21. Berk P D, Goldberg J D, Donovan P B, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-143.
22. Mesa R A, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and t reatment (IWG-MRT). Leuk Res 2007;31:737-740.
23. Moliterno A R, Williams D M, Rogers O, et al. Molecular mimicry in the chronic myeloproliferative disorders: Reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006;108:3913-3915.
24. Videbaek A. Polycythaemia vera. Course and prognosis. Acta Med Scand 1950;138:179-187.
25. Giona F, Teofili L, Moleti ML, et al. Th rombocythemia and polycythemia in patients younger than 20 years at diagnosis: Clinical and biologic features, treatment, and long-term outcome. Blood 2012;119:2219-2227.
26. Landgren O, Goldin LR, Kristinsson SY, et al. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood 2008;112:2199-2204.
27. Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007;25:5630-5635.
28. Stein BL, Williams DM, Wang NY, et al. Sex diff erences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 2010;95:1090-1097.
29. Stein BL, Rademaker A, Spivak JL, et al. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis 2011;2011:874146.
30. Colaizzo D, Amitrano L, Tiscia G L, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. JTh romb Haemost 2007;5:55-61.
31. Colaizzo D, Tiscia GL, Bafunno V, et al. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Thromb Res 2011;128:233-236.
32. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis :A report on 241 cases. Blood 2008;111:4922-4929.
33. LandolfiR, Di Gennaro L, Nicolazzi M A, et al. Polycythemia vera: Gender-related phenotypic diff erences. Intern Emerg Med 2012;7:509-515.
34. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera :The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-1579.
35. J, Li CY, et al. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007;138:354-358.
36. LandolfiR, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-2452.
37. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007;21:1952-1959.
38. De Stefano V, Za T, Rossi E, et al. Increased risk of recurrent thrombosis in patients wiThessential thrombocythemia carrying the homozygous JAK2 V617F mutation. Ann Hematol 2010;89:141-146.
39. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006;44:1528-1534.
40. Villani L, Bergamaschi G, Primignani M, et al. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCRABL negative classic myeloproliferative neoplasms. Leuk Res 2012;36: E7-e9.
41. Smalberg JH, Koehler E, Darwish Murad S, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood 201114;117:3968-3973.
42. Kouroupi E, Kiladjian JJ, Chomienne C, et al. The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood 2011;117:5777-5778.
43. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood 2008;111:3383-3387.
44. Silver RT, Vandris K, Wang YL, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially aff ected by therapy. Leuk Res 2011;35:177-182.
45. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferonalfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112:3065-3072.
46. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-5424.
47. Verstovsek S, Passamonti F, Rambaldi A, et al. Durable responses with the JAK1/JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood 2010;116:Abstract 313.
48. Hasselbalch HC. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011;4:637-655.